Intralesional Therapy for Patients with Cutaneous Malignancies
			
			
Don’t forget about intralesional therapy as a treatment option for cutaneous malignancies, including non-melanoma and melanoma skin cancers, says Dr. Vishal A. Patel, director of cutaneous oncology at the GW Cancer Center. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Patel, who shared in which patients intralesional therapy may be … 
			
		
		
Don’t forget about intralesional therapy as a treatment option for cutaneous malignancies, including non-melanoma and melanoma skin cancers, says Dr. Vishal A. Patel, director of cutaneous oncology at the GW Cancer Center. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Patel, who shared in which patients intralesional therapy may be … Continue reading "Intralesional Therapy for Patients with Cutaneous Malignancies"
	
Basal cell carcinoma (BCC) is the most common human cancer. When curative surgery and radiotherapy are contraindicated, systemic agents targeting the hedgehog signaling pathway are invaluable options for this subset of adult patients with locally advanced BCC (laBCC). Vismodegib and sonidegib are oral options with similar efficacy and side effect profiles. With the absence of head-to-head comparis … 
This patient has had over 200 of these lesions. What is the most likely genodermatosis?
A. Cowden
B. Birt-Hogg-Dube
C. Gorlin syndrome
D. Carney
E. Bannayan-Riley-Ruvalcaba
To find out the correct answer and read the explanation, click here. … 
During the 2023 Skin of Color Update in New York City, esteemed experts, Dr. Andrew Alexis, Professor of Clinical Dermatology at Weill Cornell Medical College, and Dr. George Han, Associate Professor in the Department of Dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, shared their expertise in diagnosing and managing psoriasis in individuals with skin of color … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Pearl E. Grimes, symposium chair and clinical professor of dermatology at the University of California, Los Angeles. Hear the “why” behind the Pigmentary Disorders Exchange Symposium from its founding chair. Learn what Dr. Grimes believes is a common myth about pigmentary disorders. Plus hear what m …